ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) insider James Kihara sold 4,073 shares of the company's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $68,467.13. Following the completion of the sale, the insider now owns 19,863 shares of the company's stock, valued at approximately $333,897.03. This trade represents a 17.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
ACADIA Pharmaceuticals Stock Performance
ACAD opened at $16.21 on Wednesday. The business's fifty day moving average is $15.60 and its two-hundred day moving average is $15.99. The company has a market cap of $2.70 billion, a price-to-earnings ratio of 20.78 and a beta of 0.38. ACADIA Pharmaceuticals Inc. has a one year low of $14.15 and a one year high of $32.59.
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold | Ad
Trump's back in the White House, but Wall Street is pissed.
Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.06. The company had revenue of $250.40 million for the quarter, compared to the consensus estimate of $248.83 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. ACADIA Pharmaceuticals's quarterly revenue was up 18.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.40) earnings per share. On average, analysts predict that ACADIA Pharmaceuticals Inc. will post 0.72 EPS for the current fiscal year.
Institutional Trading of ACADIA Pharmaceuticals
A number of institutional investors have recently bought and sold shares of ACAD. Park Place Capital Corp purchased a new stake in ACADIA Pharmaceuticals during the third quarter worth $25,000. Values First Advisors Inc. purchased a new stake in shares of ACADIA Pharmaceuticals in the third quarter valued at $27,000. Covestor Ltd lifted its position in shares of ACADIA Pharmaceuticals by 70.5% in the first quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 840 shares in the last quarter. Quest Partners LLC lifted its position in shares of ACADIA Pharmaceuticals by 42.3% in the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company's stock valued at $54,000 after acquiring an additional 1,047 shares in the last quarter. Finally, Stonepine Capital Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals in the second quarter valued at $81,000. 96.71% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research firms recently commented on ACAD. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. UBS Group dropped their target price on ACADIA Pharmaceuticals from $25.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, August 8th. Cantor Fitzgerald dropped their target price on ACADIA Pharmaceuticals from $37.00 to $28.00 and set an "overweight" rating on the stock in a report on Wednesday, August 7th. Royal Bank of Canada dropped their target price on ACADIA Pharmaceuticals from $29.00 to $26.00 and set an "outperform" rating on the stock in a report on Wednesday, August 7th. Finally, Morgan Stanley lowered ACADIA Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $28.00 to $20.00 in a report on Wednesday, August 7th. Six research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $25.56.
Read Our Latest Stock Report on ACADIA Pharmaceuticals
About ACADIA Pharmaceuticals
(
Get Free Report)
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
